Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome
- PMID: 16830022
Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome
Abstract
Objective: To evaluate the prognostic factors affecting morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome cases.
Methods: We retrospectively evaluated, 2245 cases who delivered in the Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, Turkey between January and December 2002. Ninety-three cases had severe preeclampsia, 26 cases eclampsia, 19 cases HELLP syndrome, and 6 cases with eclampsia and HELLP syndrome were included in this study. The pregnancy induced hypertension cases were evaluated retrospectively for socioeconomic status, obstetrical history, biochemical parameters, and maternal complications.
Results: The incidence of preeclampsia was 20.1% (453/2245), the incidence of severe preeclampsia, eclampsia, and HELLP syndrome was 6.4% (144/2245). These ratios are higher than that reported in the English literature. The complication rate was 38% in severe preeclampsia cases. Among the severe preeclampsia cases, 32 had eclampsia (22.1%), and 25 had HELLP syndrome (17.3%).
Conclusion: The most important biochemical marker for maternal mortality is bilirubin levels. Maternal mortality was statistically higher in cases with jaundice. Also, there was a statistically significant relation between maternal complications and liver function tests, lactate dehydrogenase levels, and low platelet levels.
Similar articles
-
Are maternal and fetal parameters related to perinatal mortality in HELLP syndrome?Arch Gynecol Obstet. 2011 Jun;283(6):1227-32. doi: 10.1007/s00404-010-1534-x. Epub 2010 Jun 6. Arch Gynecol Obstet. 2011. PMID: 20526778
-
HELLP syndrome: the experience at Ile-Ife, Nigeria.J Obstet Gynaecol. 2009 Apr;29(3):195-9. doi: 10.1080/01443610902753945. J Obstet Gynaecol. 2009. PMID: 19358023
-
[Difference between preeclampsia, HELLP syndrome and eclampsia, maternal evaluation].Ginecol Obstet Mex. 1996 Aug;64:377-82. Ginecol Obstet Mex. 1996. PMID: 8925990 Spanish.
-
[HELLP syndrome].Zentralbl Gynakol. 1994;116(4):195-201. Zentralbl Gynakol. 1994. PMID: 8023604 Review. German.
-
[Hypertension in pregnancy].Lijec Vjesn. 2006 Nov-Dec;128(11-12):357-68. Lijec Vjesn. 2006. PMID: 17212198 Review. Croatian.
Cited by
-
Angiotensin Type 2 Receptor Gene Polymorphisms and Susceptibility to Preeclampsia.J Reprod Infertil. 2018 Apr-Jun;19(2):95-99. J Reprod Infertil. 2018. PMID: 30009143 Free PMC article.
-
LDH (Lactate Dehydrogenase): A Biochemical Marker for the Prediction of Adverse Outcomes in Pre-eclampsia and Eclampsia.J Obstet Gynaecol India. 2016 Feb;66(1):23-9. doi: 10.1007/s13224-014-0645-x. Epub 2014 Dec 2. J Obstet Gynaecol India. 2016. PMID: 26924903 Free PMC article.
-
Evaluation of serum biomarkers for detection of preeclampsia severity in pregnant women.Pak J Med Sci. 2018 Jul-Aug;34(4):869-873. doi: 10.12669/pjms.344.14393. Pak J Med Sci. 2018. PMID: 30190744 Free PMC article.
-
Investigating the prevalence and associated factors of elevated liver enzymes and dyslipidemia during pregnancy.Sci Rep. 2025 Feb 1;15(1):3967. doi: 10.1038/s41598-025-88798-4. Sci Rep. 2025. PMID: 39893319 Free PMC article.
-
Lactic dehydrogenase: a biochemical marker for preeclampsia-eclampsia.J Obstet Gynaecol India. 2011 Dec;61(6):645-8. doi: 10.1007/s13224-011-0093-9. Epub 2012 Jan 4. J Obstet Gynaecol India. 2011. PMID: 23204682 Free PMC article.